Market Access News | pharmaphorum

News

NICE says yes to J&J, AbbVie first-line leukaemia regimen

Patients in England with chronic lymphocytic leukaemia (CLL) will be able to access a new combination therapy based on Johnson & Johnson’s Imbruvica plus AbbVie’s Venc

News

Roche’s Polivy gets FDA OK in frontline lymphoma

The FDA has set aside reservations it had about the use of Roche’s Polivy as a first-line treatment with chemotherapy for diffuse large B-cell lymphoma (DLBCL), and cleare

News

AbbVie gets key FDA OK for migraine drug Qulipta

AbbVie has carved out a niche for its migraine drug Qulipta in a competitive market, after claiming FDA approval for the product in the prevention of chronic migraine.

News

Rexulti backed for Alzheimer’s agitation by FDA adcomm

Otsuka and Lundbeck’s antidepressant Rexulti should be approved to treat Alzheimer’s disease-related agitation (AAD), according to FDA advisors – a move that could unlock

News

FDA clears Gamida’s cord blood therapy for cancer patients

The FDA has approved a stem cell-based therapy for cancer patients from Israeli biotech Gamida Cell that is designed to help them recover more quickly from aggressive chem

News

SCOTUS blocks restrictions on abortion pill mifepristone

In the latest twist and turn of the rancorous abortion pill battle in the US, the Supreme Court has temporarily halted a lower court ruling that would have restricted acce

NICE says yes to J&J, AbbVie first-line leukaemia regimen

Roche’s Polivy gets FDA OK in frontline lymphoma

AbbVie gets key FDA OK for migraine drug Qulipta

Rexulti backed for Alzheimer’s agitation by FDA adcomm

FDA clears Gamida’s cord blood therapy for cancer patients

SCOTUS blocks restrictions on abortion pill mifepristone

NHS study will pick apart mental illness with data science

How to meet your physicians where they are online

News

Editor's Picks